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BACKGROUND: There are many treatment options for metastatic colorectal cancer (CRC). However, to the authors’ knowledge,
national treatment patterns for metastatic CRC, and the stability of hospital treatment patterns over time, have not been well
described. METHODS: Data from the 2006 through 2011 National Cancer Data Base were used to study adults with newly diagnosed
metastatic CRC (84,161 patients from 1051 hospitals). Using hierarchical models, the authors characterized hospital volume in the use
of different treatment modalities (primary site resection, metastatic site resection, chemotherapy, and palliative care). The authors
then assessed variation in the receipt of treatment according to the hospitals’ relative volume of services used. Finally, the extent to
which hospital treatment patterns changed over the past decade was examined. RESULTS: Overall use of volume of services varied
widely (5.0% in the hospitals with low volumes of service to 22.3% in the hospitals with high volumes of service). As hospitals’ vol-
umes of services increased, adjusted rates of metastatic site surgery (6.6% to 30.8%; P<.001) and multiagent chemotherapy (37.8% to
57.4%; P<.001) use increased, but primary site resection demonstrated little variation (56.8% vs 59.5%; P5.024). It is interesting to
note that use of palliative care also increased (8.1% to 11.3%; P5.002). Hospital treatment patterns did not change over time, with
hospitals with high volumes of service consistently using more metastatic site resection and multiagent chemotherapy than hospitals
with low volumes of service. CONCLUSIONS: There is wide variation in hospital treatment patterns for patients with metastatic CRC,
and these patterns have been stable over time. It appears that much of the approach for metastatic CRC treatment depends on the
hospital in which the patient presents. Cancer 2015;121:1755-61. VC 2015 American Cancer Society.
KEYWORDS: metastasis, colorectal cancer, metastatic, hospital variation, patterns of care.
INTRODUCTION
Nearly 20% of patients with colorectal cancer (CRC) present with metastasis at the time of diagnosis.1-3 Historically, liver
metastasis portended a dismal prognosis because of limited therapeutic options.2,4 However, over the last 20 years, there
have been expansions in both systemic treatment options and liver-directed interventions, including improved results
with liver surgery because of better techniques and more specialty-trained surgeons.5-12 With contemporary treatment
modalities, recent reports cite a nearly 30-month survival among patients with metastatic CRC, compared with historic
survival rates of 8 months without treatment.13-15
Nevertheless, to the best of our knowledge, there is little consensus regarding optimal treatments for this patient pop-
ulation,16,17 and increasing concerns that patients are not being appropriately referred for chemotherapy and surgical
resection.18,19 To date, national patterns of care for patients with metastatic CRC have not been well described. Although
decisions for any given patient with metastatic CRC depend on clinicopathologic characteristics and individual preferen-
ces, it is possible that treatments are influenced by where a patient presents for care. In addition, the question of how
quickly clinical advances for metastatic CRC diffuse across the country has not been fully examined previously.
In the current study, we used national clinical registry data to assess treatment patterns for patients with metastatic
CRC. Our goal was to determine the degree to which different treatment modalities such as metastatic site surgery or
multiagent chemotherapy can characterize a hospital’s overall “aggressiveness” in treatment. We also assessed what
hospital attributes were associated with treatment, and to what extent treatment patterns have changed over the past
decade.
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MATERIALS AND METHODS
Data Source and Study Population
We used data from the National Cancer Data Base
(NCDB) Participant User File (PUF). The NCDB is a
joint project of the American College of Surgeons Com-
mission on Cancer (CoC) and the American Cancer Soci-
ety. Data from >1500 CoC-accredited hospitals represent
nearly 70% of all newly diagnosed patients with cancer in
the United States and are collected using standardized cod-
ing schemata. Details of data abstraction have been previ-
ously described, and it is important to note that CoC
programs are required to identify treatment that their
patients received from all sources, even if the treatment
occurred at facilities other than theirs.20,21 To allow for
attribution of 1 patient to 1 hospital, patients were assigned
to a CoC-accredited hospital for analysis if they received
their first treatment course at the reporting facility.
We identified all patients aged >17 years who pre-
sented with metastatic cancer of the colon, rectosigmoid,
or rectum from 2006 through 2011 using International
Classification of Diseases for Oncology, 3rd Edition topo-
graphical and histology codes. Patients with unknown
treatment status or who were missing information regard-
ing metastatic disease assessment were excluded from
analysis. We also excluded patients who were treated at
hospitals with <20% chemotherapy administration for
AJCC stage III CRC because this likely reflects incom-
plete documentation,22,23 and patients at hospitals with a
very low annual volume of patients with stage IV disease
(<5 patients with stage IV metastatic CRC per year) to
reduce random variation caused by small sample sizes.
To stratify hospitals for analysis, we defined use of a
high volume of services based on the percentage of
patients in each hospital receiving all 3 of the following
modalities for their disease: primary site resection, meta-
static site resection, and chemotherapy (single-agent or
multiagent). Metastatic site resection was defined as resec-
tion of disease from distant organ sites and/or distant
(nonregional) lymph node basins. Surgical treatment
denoted in the PUF as palliative care treatment was not
considered metastatic site resection. Other outcomes
included receipt of single-agent or multiagent chemother-
apy, primary site resection (excluding destruction, fulgu-
ration, and transanal excisions when used as a solitary
treatment), and palliative care.
Statistical Analysis
Variation in hospital volumes of service
We first assessed variation in treatment strategies among
hospitals. To do this, we used random intercept hierarchi-
cal logistic regression models specifying the hospital as the
higher level, and adjusted all outcomes for patient age,
sex, and race, as well as their interactions, patient primary
insurer, median ZIP code income and education levels,
Charlson/Deyo score,24 and primary tumor location as
covariates. Hierarchical models account for within-
hospital and between-hospital outcome variation and
minimize the influence of random variation from small
sample sizes on model-based estimates.25-27 Hospitals
were grouped into equal quintiles of use (“volumes of
service”) based on the adjusted percentages of patients
undergoing primary and metastatic site resections as well
as chemotherapy.
Patient demographics and tumor characteristics as
well as hospital attributes (CoC accreditation status and
US census region) were compared across hospital quin-
tiles, ranging from hospitals with low volumes of service
(HLVS) to hospitals with high volumes of service
(HHVS). In addition, we examined adjusted rates of
chemotherapy use (single-agent and multiagent), primary
site resection, metastatic site resection, and use of pallia-
tive care services to determine the relative use of treat-
ments across hospital quintiles.
Hospital treatment patterns over time
We assessed temporal changes in hospital treatment pat-
terns. To achieve this, we used additional data from the
NCDB PUF for the years 2003 and 2004 to characterize
hospitals’ volumes of service between 2003 and 2004 and
grouped them into quintiles using the same methods
described above. We then used hospitals’ volumes of serv-
ice from 2003 through 2004 as a benchmark to compare
their treatment rates over 3 subsequent time periods:
2005 through 2006, 2007 through 2008, and 2009
through 2011. The earlier data points were not used for
the primary analysis. Specifically, we assessed adjusted
rates of overall volumes of service, as well as use of primary
site resection, metastatic site resection, multiagent chemo-
therapy, and palliative care for each time period.
Finally, to assess the robustness of our findings, we
performed several sensitivity analyses. In one, we restricted
the study cohort to patients with definitive T classification
of their primary tumor because these patients were more
likely to have undergone resection of their primary site of
disease. In another, we restricted the cohort to “average-
risk” patients, defined a priori as those aged <80 years,
who did not refuse any treatment modality, and who were
not deemed to be high risk by their treating physician. In
another, we excluded treatment with single-agent chemo-
therapy, thereby only defining aggressive treatment as
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multiagent chemotherapy in addition to primary site and
metastatic site resections.
We performed all statistical analyses using Stata
Release 12 statistical software (StataCorp LP, College Sta-
tion, TX). All reported P values were 2-sided with alpha
set at P5 .05. Model discrimination was evaluated using
the c-statistic and calibration was assessed with the
Hosmer-Lemeshow goodness-of-fit test.28,29 The study
protocol was reviewed and deemed “not regulated” by the
University of Michigan Institutional Review Board.
RESULTS
We initially identified 107,393 patients with metastatic
CRC in the NCDB PUF for 2006 through 2011. After
applying exclusion criteria, the cohort included 84,161
patients treated in 1051 hospitals, as shown in Figure 1.
Over the study period, 48,525 patients (57.7%) under-
went nonpalliative primary site resection, 47,026 patients
(55.9%) received chemotherapy (40,203 [47.8%] of
whom received multiagent and 6823 [8.1%] of whom
received single-agent treatments), and 15,847 patients
(18.8%) underwent nonpalliative resection of metastatic
disease. All 3 therapies were used in 8688 patients
(10.3%).
Patient and hospital characteristics, stratified by
quintiles, ranging from HLVS to HHVS, are shown in
Table 1. Receipt of treatments varied from 5.0% in the
HLVS hospitals to 22.3% in the HHVS (P for trend
<.001). Compared with the HLVS quintile, patients in
the HHVS were, on average, slightly younger, more fre-
quently black, more likely to have private insurance, and
more likely to have multiple comorbid conditions as
measured by a Charlson/Deyo score of at least 2.
Hospitals in the HHVS quintile were more likely to have
an academic/research classification (28.6% vs 16.6%) and
were more likely located in the Great Lakes/Midwest
regions (35.7% vs 19.9%) compared with those in the
HLVS quintile. There was a relative decrease in the repre-
sentation of comprehensive community cancer centers in
the HHVS quintile (52.9% vs 61.1%). Patient volumes
were higher in the HHVS quintile hospitals (18.9 vs 14.0
patients/year).
Variation in treatment modalities as well as palliative
care use across hospitals is shown in Figure 2. What con-
stituted the services rendered for cancer treatment varied
across hospitals. For example, rates of metastatic site sur-
gery varied the most across hospitals (6.6% in the HLVS
to 30.8% in the HHVS; P for trend <.001), whereas pri-
mary site resections varied the least (56.8% vs 59.5%,
respectively; P for trend5 .024). Use of multiagent chem-
otherapy increased as hospital overall aggressiveness
increased (37.8% to 57.4%; P for trend <.001), whereas
use of single-agent chemotherapy was found to be similar
across hospitals (8.1% to 8.3%; P for trend5 .249).
Adjusted rates of palliative care were lowest in the HLVS,
and tended to increase as volumes of service increased
(8.1% to 11.3%; P for trend, .002). The study cohort for
2003 through 2011 that was used to assess temporal
changes in treatment included 114,068 patients. In gen-
eral, the past treatment patterns of hospitals were strong
predictors of their future treatment patterns, and differen-
ces between hospitals with regard to their rates of therapy
use did not appreciably change over time, as shown in Ta-
ble 2. HHVS (based on past treatment rates) had consis-
tently higher rates of metastatic site resection, multiagent
chemotherapy, and palliative care use compared with
HLVS over time. Table 2 displays the adjusted odds of
receiving various treatments for patients treated in HHVS
versus HLVS based on past treatment patterns, after
accounting for patient age, sex, race, insurance type, ZIP
code-level income and education levels, comorbidities,
and primary tumor location. For example, between 2005
and 2006, patients treated in HHVS versus HLVS had
2.85 the odds (95% confidence interval, 2.38-3.40) of
undergoing metastatic site surgery. Between 2009 and
2011, the same patients had 2.08 the odds (95% confi-
dence interval, 1.75-2.47) of undergoing metastatic site
surgery. In contrast, primary site resection rates were simi-
lar across quintiles over time, and converged by the most
recent time period evaluated.
The sensitivity analyses confirmed the trends we
observed. Variation in hospital relative volumes of service
and its components persisted when assessing “average-
Figure 1. Study cohort derivation is shown. NCDB indicates
National Cancer Data Base; PUF, Participant User File.
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risk” patients or those with liver-only metastases. When
excluding patients aged >80 years and without a high
comorbidity burden, hospital treatment rates were gener-
ally higher, but the stability of treatment patterns persisted
in the same fashion as above. When assessing patients
with definitive T classifications, rates of receipt of multi-
agent chemotherapy and metastatic site surgery were
increased overall, but with persistent variation noted
across hospitals and the same overall temporal trends as in
the primary analysis. Differences in hospital characteris-
tics across the quintiles demonstrated the same trends as
in the primary analysis.
DISCUSSION
Using national clinical registry data, the results of the cur-
rent study demonstrated broad variation in hospital treat-
ment patterns for metastatic CRC. There were wide
differences noted in the volumes of service rendered,
driven in large part by differential rates of metastatic site
resection and chemotherapy use across hospitals, rather
than differential rates of primary site resection. It is inter-
esting to note that hospitals’ volume of cancer-directed
treatments paralleled their use of palliative care services.
Higher volumes of service were notably observed in hospi-
tals with higher levels of cancer center accreditation.
TABLE 1. Hospital and Patient Characteristics Across Quintiles of Hospital Volumes of Servicea
Quintile of hospital volumes of service Q1 HLVS Q2 Q3 Average Q4 Q5 HHVS
No. of hospitals 211 210 210 210 210
Adjusted receipt of high volumes
of service, % of patients
5.0 7.8 10.6 14.7 22.3
Hospital Characteristics No. of Hospitals (%)
Mean no. of patients with AJCC stage
IV disease/y (SD)b
13.8 (8.4) 13.3 (9.6) 16.1 (11.7) 16.0 (10.8) 18.9 (15.6)
Facility typeb
Community cancer center 45 (21.3) 59 (28.1) 43 (20.5) 44 (21.0) 39 (18.6)
Comprehensive community cancer center 129 (61.1) 130 (61.9) 122 (58.1) 112 (53.3) 111 (52.9)
Academic/research cancer center 35 (16.6) 21 (10.0) 44 (21.0) 54 (25.7) 60 (28.6)
Facility census regionb
Atlantic 27 (12.8) 32 (15.2) 37 (17.6) 34 (16.2) 27 (12.9)
Northeast 8 (3.8) 18 (8.6) 14 (6.7) 20 (9.5) 11 (5.2)
Great Lakes/Midwest 43 (20.4) 43 (20.5) 51 (24.3) 70 (33.3) 77 (36.7)
Mountain/West/Pacific 71 (33.7) 63 (30.0) 54 (25.7) 40 (19.1) 30 (14.3)
South/Southeast 62 (29.4) 54 (25.7) 53 (25.2) 46 (21.9) 65 (31.0)
Patient Characteristics No. of Patients (%)
Mean age (SD), yb 65.9 (13.9) 66.6 (14.1) 66.3 (13.9) 65.7 (14.2) 64.5 (14.2)
Female sex 7312 (47.9) 6788 (47.9) 8259 (47.9) 8313 (48.4) 9651 (47.6)
Raceb
White 10,339 (67.7) 9662 (68.1) 12,054 (69.9) 11,897 (69.3) 14,259 (70.3)
Black 2357 (15.4) 1816 (12.8) 2270 (13.2) 2370 (13.8) 3070 (15.1)
Hispanic 970 (6.4) 1176 (8.3) 1094 (6.3) 688 (4.0) 612 (3.0)
Asian/Pacific Islander 494 (3.2) 470 (3.3) 398 (2.3) 406 (2.4) 460 (2.3)
Other 1107 (7.3) 1056 (7.4) 1437 (8.3) 1805 (10.5) 1894 (9.3)
High school degree by ZIP code (%)b
>80% 7107 (46.6) 6673 (47.1) 6910 (40.1) 6529 (38.0) 8350 (41.1)
80% 7412 (48.5) 6691 (47.2) 9200 (53.3) 9725 (56.7) 10,811 (53.3)
Unknown 748 (4.9) 816 (5.8) 1143 (6.6) 912 (5.3) 1134 (5.6)
ZIP code-level median incomeb
<$34,999 5858 (38.4) 4578 (32.3) 5706 (33.1) 5385 (31.4) 6712 (33.1)
>$35,000 8663 (56.7) 8787 (62.0) 10,404 (60.3) 10,869 (63.3) 12,449 (61.3)
Unknown 746 (4.9) 815 (5.7) 1143 (6.6) 912 (5.3) 1134 (5.6)
Primary insurerb
Private 4950 (32.4) 4830 (34.1) 5913 (34.3) 6171 (35.9) 7769 (38.3)
Medicare 7486 (49.0) 7215 (50.9) 8749 (50.7) 8377 (48.8) 9749 (48.0)
Other 1789 (11.7) 1402 (9.9) 1649 (9.6) 1755 (10.2) 1884 (9.3)
Not insured 1042 (6.8) 733 (5.2) 942 (5.5) 863 (5.0) 893 (4.4)
Charlson/Deyo score 2b 1058 (6.9) 985 (6.9) 1282 (7.4) 1350 (7.9) 1563 (7.7)
Primary tumor locationb
Colon 11,436 (74.9) 10,650 (75.1) 12,793 (74.1) 12,732 (74.2) 14,983 (73.8)
Rectosigmoid junction 1306 (8.6) 1187 (8.4) 1500 (8.7) 1412 (8.2) 1691 (8.3)
Rectum 2525 (16.5) 2343 (16.5) 2960 (17.2) 3022 (17.6) 3621 (17.8)
Abbreviations: HHVS, hospitals with high volumes of service; HLVS, hospitals with low volumes of service; Q, quintile; SD, standard deviation.
aModels used to derive hospital-adjusted service volumes accounted for patient age, sex, race, insurance type, ZIP code-level income and education levels,
comorbidities, and primary tumor location.
bUnivariate P value was <.05 (derived from analysis of variance/Pearson chi-square test).
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Moreover, hospitals’ treatment patterns were stable over
the past decade. These findings suggest that, to a large
degree, the treatment of patients with metastatic CRC is
dictated not by the disease itself, but by the cancer pro-
gram in which the patient is treated.
Patterns in metastatic CRC treatment have been dif-
ficult to define. In the current study, we found structural
and regional differences across volumes of service, suggest-
ing that both area-level and hospital-level attributes con-
tribute to differences in treatment. Regional differences in
resource use and intensity of care are well described, both
from a cost and payment perspective.30-32 Similar varia-
tion in volumes of service at a hospital level are noted in
this large database. These findings suggest that although
clinicopathologic factors certainly influence treatment,
much of the approach toward metastatic CRC depends
on the hospital at which the patient is treated. It is inter-
esting to note that those hospitals with the highest vol-
umes of service for the treatment of metastatic CRC also
generally had a higher use of palliative care. This finding
may reflect nuanced differences in the philosophy of those
hospitals toward overall cancer care in general, rather than
simply offering “aggressive” care to every patient. Varia-
tion within any given hospital could certainly reflect
patient preferences, but also could reflect how physicians
within a certain hospital approach treatments differently
and whether that is more highly influenced by patient or
provider characteristics is unknown.
In addition to displaying broad variability, hospital
treatment patterns were found to be largely unchanged
over the past decade. For other cancers with poor progno-
ses (eg, esophagus, pancreas), there has been a trend to-
ward offering more surgical treatments to older and sicker
patients.33 To the best of our knowledge, whether patients
with metastatic CRC are treated similarly has not been as
extensively investigated on a national basis. The comple-
ment of efficacious therapies for metastatic disease,
including chemotherapy, biological agents, surgical resec-
tion, and nonsurgical liver-directed interventions, contin-
ues to expand.6,7,13,16,34 At the same time, there are more
specialty-trained liver surgeons and overall decreases in
morbidity and mortality associated with liver surgery.12,35
Despite this, it appears that these advances have not been
promulgated across the country and may be limited only
to a subset of hospitals that may have already demon-
strated an approach toward overall cancer care that is
demonstrated by not only generally higher volumes of
service but a higher use of palliative care.
It is also possible that differential knowledge and
understanding of the treatment options for metastatic
CRC breeds variation in care patterns. It has been demon-
strated that rates of adherence to recommended treatment
measures for cancer are highly correlated with the level of
evidence supporting them.36,37 In contrast with other
stages of CRC, to the best of our knowledge there are
fewer standardized treatments for metastatic disease that
Figure 2. Treatment modality variation is shown across levels of hospital volume of services. chemo indicates chemotherapy;
Q, quintile.
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carry strong guideline endorsement and there are few
guidelines for the use of palliative services.17,31,36,37 Fur-
thermore, the indications and timing for resection, both
for the primary tumor and metastases, continue to
evolve.9,13,16,38,39 Finally, emerging evidence suggests
substantial heterogeneity in physicians’ understanding of
what constitutes “resectable” disease.18,40,41
There are important limitations to the current study.
First, we were unable to assess the extent to which treat-
ment represented appropriate care. However, our intent
was to provide an assessment of variations in national treat-
ment patterns independent of inferences regarding appro-
priate care at the individual patient level. Similarly, due to
limitations of the PUF data, we could not assess factors rel-
evant to patient selection, surgical decision-making (eg,
size and location of metastases), and type and sequencing
of multimodality treatments (eg, choice of agents and use
of agents preoperatively or postoperatively). However, the
observed variation in resection rates was not substantially
altered when focusing on “average-risk” patients or
patients with liver-only metastases, and therefore is
unlikely to be fully explained by differences in patients’
resectability. Second, we were unable to assess patients
with metachronous metastatic disease due to the lack of
these types of data in the NCDB PUF. As such, the results
of the current study should be interpreted within the con-
text of patients with metastatic disease at the time of pre-
sentation. Third, we could not assess use of certain liver-
directed interventions (such as radiofrequency ablation or
transarterial chemoembolization) if they were not included
as a part of a surgical procedure. Finally, these data repre-
sent a group of hospitals meeting stringent structural, pro-
cess, and patient volume accreditation requirements by the
CoC, which tend to be generally larger, more frequently
urban, and have more cancer-related services available to
patients than other hospitals.42 These results may not be
generalizable to all hospitals, but these data are representa-
tive of the vast majority of hospitals in the United States
most likely to treat this patient population, although refer-
ral patterns are not able to be defined.
There is broad variation in how hospitals approach
the treatment of patients with metastatic CRC, including
the use of palliative care services. Moreover, the stability
of hospitals’ treatment patterns suggests that a particular
hospital’s generalized approach to cancer care may have as
strong an influence on a patient’s treatment as their dis-
ease status. Why such differences in treatment patterns
persist are unclear because improved outcomes after cer-
tain treatment strategies are widely reported in the litera-
ture. Improvement of care may involve improved
knowledge dissemination, increased multidisciplinary col-
laboration between medical and surgical oncologists in
treatment decisions, and, when appropriate, increased
referral to specialty centers for patients with metastatic
CRC.
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